Royal Bank of Canada Trims Humana (NYSE:HUM) Target Price to $265.00

Humana (NYSE:HUM) had its target price reduced by Royal Bank of Canada from $400.00 to $265.00 in a research note released on Tuesday morning, Benzinga reports. They currently have an outperform rating on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. Bank of America lowered shares of Humana from a neutral rating to an underperform rating and cut their price target for the company from $376.00 to $247.00 in a research note on Wednesday, October 2nd. Jefferies Financial Group downgraded shares of Humana from a buy rating to a hold rating and lowered their price objective for the company from $519.00 to $253.00 in a report on Monday. Oppenheimer lowered their price objective on shares of Humana from $400.00 to $280.00 and set an outperform rating on the stock in a report on Thursday, October 3rd. UBS Group lowered their price objective on shares of Humana from $380.00 to $250.00 and set a neutral rating on the stock in a report on Friday, October 4th. Finally, Piper Sandler downgraded shares of Humana from an overweight rating to a neutral rating and lowered their price objective for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. One investment analyst has rated the stock with a sell rating, eighteen have given a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Hold and an average price target of $322.00.

Humana Stock Performance

Shares of HUM opened at $251.36 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana has a twelve month low of $213.31 and a twelve month high of $530.54. The firm’s 50 day moving average price is $329.03 and its two-hundred day moving average price is $341.40. The firm has a market cap of $30.26 billion, a P/E ratio of 17.93, a PEG ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the firm posted $8.94 earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. On average, analysts forecast that Humana will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a $0.885 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.41%. Humana’s payout ratio is presently 25.25%.

Institutional Investors Weigh In On Humana

Institutional investors have recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Atwood & Palmer Inc. bought a new stake in shares of Humana in the third quarter valued at about $29,000. Hantz Financial Services Inc. bought a new stake in shares of Humana in the second quarter valued at about $35,000. Family Firm Inc. bought a new stake in shares of Humana in the second quarter valued at about $37,000. Finally, Hollencrest Capital Management bought a new stake in Humana during the second quarter worth about $40,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.